Please refer to the PCOS section of Remedy.
Please refer to the guidelines for the management of Premature Ovarian Failure (word doc) created by Dr Rachel Brown, Gynaecology GPSI (Montpelier Health Centre)
**3/6/25**
All USS detected ovarian cysts/masses will be scored using the O-RAD US scoring system by the ultrasonographer completing the scan. This score can then be used to guide further management according to the following flow chart:
Primary Care Pathway - Ovarian Cyst/Mass on Transvaginal US
If referral is advised it is helpful if primary care clinicians can arrange the advised blood tests/ imaging at the point of referral as this will improve the timeliness of the patient’s care. These results will be reviewed and actioned by secondary care when they see the patient .
As ultrasongraphers are not trained to interpret imaging it would be helpful if requesting clinicians can advise patients that the results of the scan are unlikely to be shared at the point of scanning.
Please see CKS advice regarding indication for a CA125 test and interpretation of results:
CA125 can be used to investigate symptomatic patients where there are concerns that their symptoms could be caused by ovarian cancer, this includes patients with non-specific symptoms who are being investigated before referral on the Non- Specific Symptoms USC (2WW) pathway.
Please note that a raised CA125 alone is not an indication for an USC (2WW) referral. See the Gynaecology - USC (2WW) page for further details and indications for referral.This page also has a CA125 flow chart which may be helpful and also has advice on other causes of raised CA125 if ovarian cancer is excluded.
Patient Leaflet
(1) Managing a woman with suspected ovarian cancer - CKS
(2) CA-125 Blood Test: Results, Normal Range & What To Expect (clevelandclinic.org)
Efforts are made to ensure the accuracy and agreement of these guidelines, including any content uploaded, referred to or linked to from the system. However, BNSSG ICB cannot guarantee this. This guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, in accordance with the mental capacity act, and informed by the summary of product characteristics of any drugs they are considering. Practitioners are required to perform their duties in accordance with the law and their regulators and nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
Information provided through Remedy is continually updated so please be aware any printed copies may quickly become out of date.